Literature DB >> 2661437

Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow.

T Schmeiser1, M Wiesneth, D Bunjes, R Arnold, B Hertenstein, W Heit, E Kurrle.   

Abstract

The infectious complications during different time intervals after allogeneic bone marrow transplantation (BMT) (day 0 to day 30, 31 to 100, 101 to 365, 366 to 730) were reviewed in 67 adult patients, 27 of whom received transplants without T-cell depletion (TCD) using methotrexate or cyclosporin A for prophylaxis of graft-versus-host disease (GvHD) and 40 of whom received donor marrow with TCD using the monoclonal anti-lymphocyte antibody campath-1 and human complement. The use of TCD reduced the incidence and severity of GvHD significantly (p less than 0.01), but was associated with an increased rate of graft rejections. During all time intervals patients with TCD had a similar, lower or statistically significantly lower number of bacterial, fungal or viral infections and a statistically significantly lower number of lethal infections (p = 0.05) as compared with patients without TCD. This finding might be explained by the fact that with TCD immunological reconstitution can take place unimpaired by GvHD or its prophylaxis or treatment, resulting in a decreased incidence of infections.

Entities:  

Mesh:

Year:  1989        PMID: 2661437     DOI: 10.1007/bf01644010

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  45 in total

Review 1.  Infection in bone marrow transplant recipients.

Authors:  J D Meyers
Journal:  Am J Med       Date:  1986-07-28       Impact factor: 4.965

2.  T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.

Authors:  M Wiesneth; B Hertenstein; D Bunjes; T Schmeiser; R Arnold; H Heimpel; W Heit
Journal:  Eur J Haematol       Date:  1988-09       Impact factor: 2.997

3.  Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

Authors:  J F Apperley; L Jones; G Hale; H Waldmann; J Hows; Y Rombos; C Tsatalas; R E Marcus; A W Goolden; E C Gordon-Smith
Journal:  Bone Marrow Transplant       Date:  1986-05       Impact factor: 5.483

Review 4.  Prevention of infection in neutropenic bone marrow transplant patients.

Authors:  T R Rogers
Journal:  Antibiot Chemother (1971)       Date:  1985

Review 5.  Marrow transplantation for malignant disease.

Authors:  E D Thomas
Journal:  Am J Med Sci       Date:  1987-08       Impact factor: 2.378

Review 6.  Infection in bone marrow transplantation.

Authors:  J D Meyers; K Atkinson
Journal:  Clin Haematol       Date:  1983-10

7.  Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation.

Authors:  D J Winston; E S Huang; M J Miller; C H Lin; W G Ho; R P Gale; R E Champlin
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

8.  Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.

Authors:  W Heit; D Bunjes; M Wiesneth; T Schmeiser; R Arnold; G Hale; H Waldmann; H Heimpel
Journal:  Br J Haematol       Date:  1986-11       Impact factor: 6.998

9.  Antimicrobial prophylaxis in neutropenic patients after bone marrow transplantation.

Authors:  T Schmeiser; E Kurrle; R Arnold; D Krieger; W Heit; H Heimpel
Journal:  Infection       Date:  1988       Impact factor: 3.553

10.  Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia.

Authors:  H J Deeg; R Storb; E D Thomas; N Flournoy; M S Kennedy; M Banaji; F R Appelbaum; W I Bensinger; C D Buckner; R A Clift
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

View more
  5 in total

1.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.

Authors:  Antonia M S Müller; Jessica A Linderman; Mareike Florek; David Miklos; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 3.  Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.

Authors:  Jan Storek; Michelle Geddes; Faisal Khan; Bertrand Huard; Claudine Helg; Yves Chalandon; Jakob Passweg; Eddy Roosnek
Journal:  Semin Immunopathol       Date:  2008-10-24       Impact factor: 9.623

Review 4.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

5.  Epidemiology and treatment approaches in management of invasive fungal infections.

Authors:  Jane Kriengkauykiat; James I Ito; Sanjeet S Dadwal
Journal:  Clin Epidemiol       Date:  2011-05-19       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.